Anti-HGF moAb. Although well-tolerated, the treatment showed very limited efficacyAnti-MUC16 moAb. While used in monotherapy, oregovomab did not show any benefit to patients with persistent advanced ovarian cancermoAb combined with first line standard chemotherapy in patients with advanced ovarian cancer showed prolongation of both PFS and OSIn patients with optimally resected advanced ovarian cancer, combination of drugs resulted in more than three times longer PFS compared to chemotherapy alone. This evidence concerns the gene MUC16 and ovarian carcinoma.